

List of 353 articles included in the systematic analysis

1. Adisakwattana P, Suwandittakul N, Petmitr S, et al (2015). ALCAM is a Novel Cytoplasmic Membrane Protein in TNF-alpha Stimulated Invasive Cholangiocarcinoma Cells. *Asian Pac J Cancer Prev*, **16**, 3849-56.
2. Amonyngcharoen S, Suriyo T, Thiantanawat A, et al (2015). Tauro lithocholic acid promotes intrahepatic cholangiocarcinoma cell growth via muscarinic acetylcholine receptor and EGFR/ERK1/2 signaling pathway. *Int J Oncol*, **46**, 2317-26.
3. Amornpisutt R, Proungvitaya S, Jearanaikoon P, et al (2015). DNA methylation level of OPCML and SFRP1: a potential diagnostic biomarker of cholangiocarcinoma. *Tumour Biol*, **36**, 4973-8.
4. Anantachoke N, Tuchinda P, Kuhakarn C, et al (2012). Prenylated caged xanthenes: chemistry and biology. *Pharm Biol*, **50**, 78-91.
5. Aneknan P, Kukongviriyapan V, Prawan A, et al (2014). Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells. *Asian Pac J Cancer Prev*, **15**, 5071-6.
6. Apisarnthanarak P, Kanchanarat K, Muangsomboon K, et al (2012). CT appearances of post-radiation livers in patients with unresectable cholangiocarcinoma. *J Med Assoc Thai*, **95**, 221-8.
7. Arimatsu Y, Kaewkes S, Laha T, et al (2015). Specific diagnosis of *Opisthorchis viverrini* using loop-mediated isothermal amplification (LAMP) targeting parasite microsatellites. *Acta Trop*, **141**, 368-71.
8. Arunsan P, Donthaisong C, Suwannatrai K, et al (2014). Localization of the cystogenous glands of *Opisthorchis viverrini* cercariae. *Southeast Asian J Trop Med Public Health*, **45**, 276-89.

9. Aukkanimart R, Boonmars T, Sriraj P, et al (2015). Anthelmintic, anti-inflammatory and antioxidant effects of *Garcinia mangostana* extract in hamster opisthorchiasis. *Exp Parasitol*, **154**, 5-13.
10. Aukkanimart RB, T.; Juasook, A.; Sriraj, P.; Boonjaraspinyo, S.; Wu, Z.; Laummuanwai, P.; Pairojkul, C.; Khuntikeo, N.; Rattanasuwan, P. (2015). Altered Expression of Oxidative Metabolism Related Genes in Cholangiocarcinomas. *Asian Pac J Cancer Prev*, **16**, 5875-81.
11. Aye Soukhathamavong P, Rajpho V, Phongluxa K, et al (2015). Subtle to severe hepatobiliary morbidity in *Opisthorchis viverrini* endemic settings in southern Laos. *Acta Trop*, **141**, 303-9.
12. Barr Fritcher EG, Voss JS, Brankley SM, et al (2015). An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples. *Gastroenterology*, **149**, 1813-24 e1.
13. Barusrux S, Nanok C, Puthisawas W, et al (2012). Viral hepatitis B, C infection and genotype distribution among cholangiocarcinoma patients in northeast Thailand. *Asian Pac J Cancer Prev*, **13 Suppl**, 83-7.
14. Bhudhisawasdi V, Talabnin C, Pugkhem A, et al (2012). Evaluation of postoperative adjuvant chemotherapy for intrahepatic cholangiocarcinoma patients undergoing R1 and R2 resections. *Asian Pac J Cancer Prev*, **13 Suppl**, 169-74.
15. Boonjaraspinyo S, Boonmars T, Kaewkes S, et al (2012a). Down-regulated expression of HSP70 in correlation with clinicopathology of cholangiocarcinoma. *Pathol Oncol Res*, **18**, 227-37.
16. Boonjaraspinyo S, Boonmars T, Wu Z, et al (2012b). Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma. *Tumour Biol*, **33**, 1785-802.

17. Boonjaraspinyo S, Juasook A, Boonmars T, et al (2015). A Promising Serum Autoantibody Marker, Anti-Heat Shock Protein 90alpha, for Cholangiocarcinoma. *Asian Pac J Cancer Prev*, **16**, 5779-85.
18. Boonjaraspinyo S, Wu Z, Boonmars T, et al (2012c). Overexpression of PDGFA and its receptor during carcinogenesis of *Opisthorchis viverrini*-associated cholangiocarcinoma. *Parasitology International*, **61**, 145-50.
19. Boonmars T, Wu Z, Boonjaraspinyo S, et al (2011). Involvement of c-Ski oncoprotein in carcinogenesis of cholangiocarcinoma induced by *Opisthorchis viverrini* and N-nitrosodimethylamine. *Pathol Oncol Res*, **17**, 219-27.
20. Boonsri K, Sritan J, Vechmanus T, et al (2013). Intrahepatic cholangiocarcinoma in a captive meerkat (*Suricata suricatta*). *J Zoo Wildl Med*, **44**, 740-3.
21. Boonyanugomol W, Chomvarin C, Hahnvajjanawong C, et al (2013). *Helicobacter pylori* cag pathogenicity island (cagPAI) involved in bacterial internalization and IL-8 induced responses via NOD1- and MyD88-dependent mechanisms in human biliary epithelial cells. *PLoS One*, **8**, e77358.
22. Boonyanugomol W, Chomvarin C, Song JY, et al (2012a). Effects of *Helicobacter pylori* gamma-glutamyltranspeptidase on apoptosis and inflammation in human biliary cells. *Dig Dis Sci*, **57**, 2615-24.
23. Boonyanugomol W, Chomvarin C, Sripa B, et al (2012b). *Helicobacter pylori* in Thai patients with cholangiocarcinoma and its association with biliary inflammation and proliferation. *HPB (Oxford)*, **14**, 177-84.
24. Boonyanugomol W, Chomvarin C, Sripa B, et al (2012c). Molecular analysis of *Helicobacter pylori* virulent-associated genes in hepatobiliary patients. *HPB (Oxford)*, **14**, 754-63.

25. Brindley PJ, da Costa JM, Sripa B (2015). Why does infection with some helminths cause cancer? *Trends Cancer*, **1**, 174-82.
26. Buayairaksa M, Kanokmedhakul S, Kanokmedhakul K, et al (2011). Cytotoxic lasiodiplodin derivatives from the fungus *Syncephalastrum racemosum*. *Arch Pharm Res*, **34**, 2037-41.
27. Bunsiripaiboon P, Sornmayura P, Wilasrusmee C, et al (2010). The prognostic significance of microvessel density in intrahepatic cholangiocarcinoma. *J Med Assoc Thai*, **93**, 66-72.
28. Bunthot S, Obchoei S, Kraiklang R, et al (2012). Overexpression of claudin-4 in cholangiocarcinoma tissues and its possible role in tumor metastasis. *Asian Pac J Cancer Prev*, **13 Suppl**, 71-6.
29. Buranrat B, Chau-in S, Prawan A, et al (2012). NQO1 expression correlates with cholangiocarcinoma prognosis. *Asian Pac J Cancer Prev*, **13 Suppl**, 131-6.
30. Buranrat B, Prawan A, Kukongviriyapan U, et al (2010). Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells. *World J Gastroenterol*, **16**, 2362-70.
31. Butthongkomvong K, Sirachainan E, Jhankumpha S, et al (2013). Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. *Asian Pac J Cancer Prev*, **14**, 3565-8.
32. Chaijaroenkul W, Viyanant V, Mahavorasirikul W, et al (2011). Cytotoxic activity of artemisinin derivatives against cholangiocarcinoma (CL-6) and hepatocarcinoma (Hep-G2) cell lines. *Asian Pac J Cancer Prev*, **12**, 55-9.
33. Chaiteerakij R, Harmsen WS, Marrero CR, et al (2014). A new clinically based staging system for perihilar cholangiocarcinoma. *Am J Gastroenterol*, **109**, 1881-90.

34. Chaiteerakij R, Juran BD, Aboelsoud MM, et al (2015). Association between variants in inflammation and cancer-associated genes and risk and survival of cholangiocarcinoma. *Cancer Med*, **4**, 1599-602.
35. Chaiyadet S, Smout M, Johnson M, et al (2015a). Excretory/secretory products of the carcinogenic liver fluke are endocytosed by human cholangiocytes and drive cell proliferation and IL6 production. *Int J Parasitol*, **45**, 773-81.
36. Chaiyadet S, Sotillo J, Smout M, et al (2015b). Carcinogenic Liver Fluke Secretes Extracellular Vesicles That Promote Cholangiocytes to Adopt a Tumorigenic Phenotype. *J Infect Dis*, **212**, 1636-45.
37. Chaiyarit P, Sithithaworn P, Thuwajit C, et al (2011). Detection of salivary antibodies to crude antigens of *Opisthorchis viverrini* in opisthorchiasis and cholangiocarcinoma patients. *Clinical Oral Investigations*, **15**, 477-83.
38. Chamadol N, Laopaiboon V, Kaewradee J, et al (2010). Comparison of computed tomographic finding of the intraductal and periductal cholangiocarcinoma. *J Med Assoc Thai*, **93**, 481-8.
39. Chamadol N, Pairojkul C, Khuntikeo N, et al (2014). Histological confirmation of periductal fibrosis from ultrasound diagnosis in cholangiocarcinoma patients. *Journal of Hepato-biliary-pancreatic Sciences*, **21**, 316-22.
40. Chan-On W, Huyen NT, Songtawee N, et al (2015). Quinoline-based clioquinol and nitroxoline exhibit anticancer activity inducing FoxM1 inhibition in cholangiocarcinoma cells. *Drug Des Devel Ther*, **9**, 2033-47.
41. Chan-On W, Nairismagi ML, Ong CK, et al (2013). Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers. *Nat Genet*, **45**, 1474-8.

42. Chin LP, Soo RA, Soong R, et al (2012). Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. *J Thorac Oncol*, **7**, 1625-30.
43. Chindaprasirt J, Sookprasert A, Sawanyawisuth K, et al (2012). Brain metastases from cholangiocarcinoma: a first case series in Thailand. *Asian Pac J Cancer Prev*, **13**, 1995-7.
44. Chong RJ, Abdullah MS, Hossain MM, et al (2013). Rising incidence of primary liver cancer in Brunei Darussalam. *Asian Pac J Cancer Prev*, **14**, 3473-7.
45. Chudthaisong N, Promthet S, Bradshaw P (2015). Risk factors for *Opisthorchis viverrini* Infection in Nong Khai Province, Thailand. *Asian Pac J Cancer Prev*, **16**, 4593-6.
46. Chuensumran U, Saelee P, Punyarit P, et al (2011a). Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation. *Asian Pac J Cancer Prev*, **12**, 775-9.
47. Chuensumran U, Saelee P, Wongkham S, et al (2011b). Histological type of intrahepatic cholangiocarcinoma differentiated by genetic alteration from AP-PCR fingerprint. *Asian Pac J Cancer Prev*, **12**, 1377-80.
48. Chusorn P, Namwat N, Loilome W, et al (2013). Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis. *Tumour Biol*, **34**, 1579-88.
49. Correia da Costa JM, Vale N, Gouveia MJ, et al (2014). Schistosome and liver fluke derived catechol-estrogens and helminth associated cancers. *Front Genet*, **5**, 444.
50. Daorueang D, Thuwajit P, Roittrakul S, et al (2012). Secreted *Opisthorchis viverrini* glutathione S-transferase regulates cell proliferation through AKT and ERK pathways in cholangiocarcinoma. *Parasitol Int*, **61**, 155-61.

51. Dechakhamphu S, Pinlaor S, Sitthithaworn P, et al (2010a). Accumulation of miscoding etheno-DNA adducts and highly expressed DNA repair during liver fluke-induced cholangiocarcinogenesis in hamsters. *Mutat Res*, **691**, 9-16.
52. Dechakhamphu S, Pinlaor S, Sitthithaworn P, et al (2010b). Lipid peroxidation and etheno DNA adducts in white blood cells of liver fluke-infected patients: protection by plasma alpha-tocopherol and praziquantel. *Cancer Epidemiol Biomarkers Prev*, **19**, 310-8.
53. Dechaphunkul A, Kanngurn S, Dechsukhum C, et al (2010). The significance of galectin-3 immunohistochemistry, clinical characteristics and liver imaging in differentiating intrahepatic cholangiocarcinoma from adenocarcinoma liver metastasis. *J Med Assoc Thai*, **93**, 523-8.
54. Decharchoochart P, Suthiwong J, Samatiwat P, et al (2014). Cytotoxicity of compounds from the fruits of *Derris indica* against cholangiocarcinoma and HepG2 cell lines. *J Nat Med*, **68**, 730-6.
55. Deenonpoe R, Chomvarin C, Pairojkul C, et al (2015). The carcinogenic liver fluke *Opisthorchis viverrini* is a reservoir for species of *Helicobacter*. *Asian Pac J Cancer Prev*, **16**, 1751-8.
56. Dokduang H, Juntana S, Techasen A, et al (2013). Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment. *Tumour Biol*, **34**, 3519-28.
57. Dokduang H, Techasen A, Namwat N, et al (2014). STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression. *J Hepatobiliary Pancreat Sci*, **21**, 767-76.
58. Donthaisong C, Arunsan P, Suwannatrai K, et al (2014). Experimental infection of *Opisthorchis viverrini* cercariae to the cyprinid fish, *Barbonymus gonionotus*. *Acta Trop*, **136**, 118-22.

59. Donthaisong C, Arunsan P, Suwannatrai K, et al (2015). Reprint of "Experimental infection of *Opisthorchis viverrini* cercariae to the cyprinid fish, *Barbonymus gonionotus*". *Acta Trop*, **141**, 253-7.
60. Duangkumpha K, Techasen A, Loilome W, et al (2014). BMP-7 blocks the effects of TGF-beta-induced EMT in cholangiocarcinoma. *Tumour Biol*, **35**, 9667-76.
61. Duangsong R, Promthet S, Thaewnongiew K (2013). Development of a community-based approach to opisthorchiasis control. *Asian Pac J Cancer Prev*, **14**, 7039-43.
62. Duenngai K, Boonmars T, Sithithaworn J, et al (2013). Diagnosis of early infection and post chemotherapeutic treatment by copro-DNA detection in experimental opisthorchiasis. *Parasitol Res*, **112**, 271-8.
63. Dutta S, Reamtong O, Panvongsa W, et al (2015). Proteomics profiling of cholangiocarcinoma exosomes: A potential role of oncogenic protein transferring in cancer progression. *Biochim Biophys Acta*, **1852**, 1989-99.
64. Forrer A, Sayasone S, Vounatsou P, et al (2012). Spatial distribution of, and risk factors for, *Opisthorchis viverrini* infection in southern Lao PDR. *PLoS Negl Trop Dis*, **6**, e1481.
65. Grundy-Warr C, Andrews RH, Sithithaworn P, et al (2012). Raw attitudes, wetland cultures, life-cycles: socio-cultural dynamics relating to *Opisthorchis viverrini* in the Mekong Basin. *Parasitol Int*, **61**, 65-70.
66. Hahnvajanawong C, Boonyanugomol W, Nasomyon T, et al (2010). Apoptotic activity of caged xanthenes from *Garcinia hanburyi* in cholangiocarcinoma cell lines. *World J Gastroenterol*, **16**, 2235-43.
67. Hahnvajanawong C, Chaiyagool J, Seubwai W, et al (2012a). Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. *World J Gastroenterol*, **18**, 3955-61.



68. Hahnvajanawong C, Ketnimit S, Pattanapanyasat K, et al (2012b). Involvement of p53 and nuclear factor-kappaB signaling pathway for the induction of G1-phase cell cycle arrest of cholangiocarcinoma cell lines by isomorellin. *Biol Pharm Bull*, **35**, 1914-25.
69. Hanpanich P, Pinlaor S, Charoensuk L, et al (2015). MRI and (1)H MRS findings of hepatobiliary changes and cholangiocarcinoma development in hamsters infected with *Opisthorchis viverrini* and treated with N-nitrosodimethylamine. *Magn Reson Imaging*, **33**, 1146-55.
70. Hanpanich P, Pinlaor S, Charoensuk L, et al (2013). MRI and (1)H MRS evaluation for the serial bile duct changes in hamsters after infection with *Opisthorchis viverrini*. *Magn Reson Imaging*, **31**, 1418-25.
71. Hematulin A, Sagan D, Sawanyawisuth K, et al (2014). Association between cellular radiosensitivity and G1/G2 checkpoint proficiencies in human cholangiocarcinoma cell lines. *Int J Oncol*, **45**, 1159-66.
72. Hemtasin C, Kanokmedhakul S, Kanokmedhakul K, et al (2011). Cytotoxic pentacyclic and tetracyclic aromatic sesquiterpenes from *Phomopsis archeri*. *J Nat Prod*, **74**, 609-13.
73. Hongsrichan N, Rucksaken R, Chamgramol Y, et al (2013). Annexin A1: A new immunohistological marker of cholangiocarcinoma. *World J Gastroenterol*, **19**, 2456-65.
74. Hotez PJ, Ehrenberg JP (2010). Escalating the global fight against neglected tropical diseases through interventions in the Asia Pacific region. *Adv Parasitol*, **72**, 31-53.
75. Hunsawong T, Singsuksawat E, In-chon N, et al (2012). Estrogen is increased in male cholangiocarcinoma patients' serum and stimulates invasion in cholangiocarcinoma cell lines in vitro. *J Cancer Res Clin Oncol*, **138**, 1311-20.

76. Hussain SM, Al-Jashamy KA (2013). Determination of chemical composition of gallbladder stones and their association with induction of cholangiocarcinoma. *Asian Pac J Cancer Prev*, **14**, 6257-60.
77. Indramanee S, Silsirivanit A, Pairojkul C, et al (2012). Aberrant glycosylation in cholangiocarcinoma demonstrated by lectin-histochemistry. *Asian Pac J Cancer Prev*, **13 Suppl**, 119-24.
78. Ito T, Sakurai-Yageta M, Goto A, et al (2014). Genomic and transcriptional alterations of cholangiocarcinoma. *Journal of Hepato-biliary-pancreatic Sciences*, **21**, 380-7.
79. Jamnongkan W, Techasen A, Thanan R, et al (2013). Oxidized alpha-1 antitrypsin as a predictive risk marker of opisthorchiasis-associated cholangiocarcinoma. *Tumour Biol*, **34**, 695-704.
80. Janan M, Proungvitaya S, Limpai boon T, et al (2012). Serum adhesion molecule-1 (ICAM-1) as a potential prognostic marker for cholangiocarcinoma patients. *Asian Pac J Cancer Prev*, **13 Suppl**, 107-14.
81. Janeklang S, Nakaew A, Vaeteewoottacharn K, et al (2014). In vitro and in vivo antitumor activity of tiliacorinine in human cholangiocarcinoma. *Asian Pac J Cancer Prev*, **15**, 7473-8.
82. Janpipatkul K, Suksen K, Borwornpinyo S, et al (2014). Downregulation of LAT1 expression suppresses cholangiocarcinoma cell invasion and migration. *Cell Signal*, **26**, 1668-79.
83. Janvilisri T, Leelawat K, Roytrakul S, et al (2015). Novel Serum Biomarkers to Differentiate Cholangiocarcinoma from Benign Biliary Tract Diseases Using a Proteomic Approach. *Dis Markers*, **2015**, 105358.

84. Jattujan P, Pinlaor S, Charoensuk L, et al (2013). Curcumin prevents bile canalicular alterations in the liver of hamsters infected with *Opisthorchis viverrini*. *Korean J Parasitol*, **51**, 695-701.
85. Jongthawin J, Chusorn P, Techasen A, et al (2014). PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression. *Tumour Biol*, **35**, 8051-64.
86. Jongthawin J, Techasen A, Loilome W, et al (2012). Anti-inflammatory agents suppress the prostaglandin E2 production and migration ability of cholangiocarcinoma cell lines. *Asian Pac J Cancer Prev*, **13 Suppl**, 47-51.
87. Juasook A, Aukkanimart R, Boonmars T, et al (2013a). Tumor-related gene changes in immunosuppressive Syrian hamster cholangiocarcinoma. *Pathol Oncol Res*, **19**, 785-94.
88. Juasook A, Boonmars T, Kaewkes S, et al (2012). Anti-inflammatory effect of prednisolone on the growth of human liver fluke in experimental opisthorchiasis. *Parasitol Res*, **110**, 2271-9.
89. Juasook A, Boonmars T, Wu Z, et al (2013b). Immunosuppressive prednisolone enhances early cholangiocarcinoma in Syrian hamsters with liver fluke infection and administration of N-nitrosodimethylamine. *Pathol Oncol Res*, **19**, 55-62.
90. Jusakul A, Khuntikeo N, Haigh WG, et al (2012a). Identification of biliary bile acids in patients with benign biliary diseases, hepatocellular carcinoma and cholangiocarcinoma. *Asian Pac J Cancer Prev*, **13 Suppl**, 77-82.
91. Jusakul A, Kongpetch S, Teh BT (2015). Genetics of *Opisthorchis viverrini*-related cholangiocarcinoma. *Curr Opin Gastroenterol*, **31**, 258-63.

92. Jusakul A, Loilome W, Namwat N, et al (2012b). Liver fluke-induced hepatic oxysterols stimulate DNA damage and apoptosis in cultured human cholangiocytes. *Mutat Res*, **731**, 48-57.
93. Jusakul A, Loilome W, Namwat N, et al (2013). Anti-apoptotic phenotypes of cholestan-3beta,5alpha,6beta-triol-resistant human cholangiocytes: characteristics contributing to the genesis of cholangiocarcinoma. *J Steroid Biochem Mol Biol*, **138**, 368-75.
94. Jusakul A, Yongvanit P, Loilome W, et al (2011). Mechanisms of oxysterol-induced carcinogenesis. *Lipids Health Dis*, **10**, 44.
95. Kaewkes W, Kaewkes S, Tesana S, et al (2012). Fecal bacterial contamination in natural water reservoirs as an indicator of seasonal infection by *Opisthorchis viverrini* in snail intermediate hosts. *Parasitol Int*, **61**, 49-51.
96. Kaewkong W, Choochote W, Kanla P, et al (2012a). Chromosomes and karyotype analysis of a liver fluke, *Opisthorchis viverrini*, by scanning electron microscopy. *Parasitol Int*, **61**, 504-7.
97. Kaewkong W, Imtawil K, Maleewong W, et al (2012b). Genome size estimation of liver fluke *Opisthorchis viverrini* by real-time polymerase chain reaction based method. *Parasitology International*, **61**, 77-80.
98. Kaewkong W, Intapan PM, Sanpool O, et al (2013). Molecular differentiation of *Opisthorchis viverrini* and *Clonorchis sinensis* eggs by multiplex real-time PCR with high resolution melting analysis. *Korean J Parasitol*, **51**, 689-94.
99. Kaewpitoon N, Kaewpitoon SJ (2015). Localization of Tubulin from the Carcinogenic Human Liver Fluke, *Opisthorchis viverrini*. *J Med Assoc Thai*, **98 Suppl 4**, S9-16.

100. Kaewpitoon N, Kaewpitoon SJ, Ueng-arporn N, et al (2012a). Carcinogenic human liver fluke: current status of *Opisthorchis viverrini* metacercariae in Nakhon Ratchasima, Thailand. *Asian Pac J Cancer Prev*, **13**, 1235-40.
101. Kaewpitoon NK, N.; Komporn, P.; Chavenkun, W.; Kujapun, J.; Norkaew, J.; Ponphimai, S.; Matrakool, L.; Tongtawee, T.; Panpimanmas, S.; Rujirakul, R.; Padchasuwan, N.; Pholsripradit, P.; Eksanti, T.; Phatisena, T.; Loyd, R. A.; Kaewpitoon, S. J. (2015). Review and Current Status of *Opisthorchis viverrini* Infection at the Community Level in Thailand. *Asian Pac J Cancer Prev*, **16**, 6825-30.
102. Kaewpitoon SJ, Loyd RA, Rujirakul R, et al (2015). Benefits of Metformin Use for Cholangiocarcinoma. *Asian Pac J Cancer Prev*, **16**, 8079-83.
103. Kaewpitoon SJ, Rujirakul R, Kaewpitoon N (2012b). Prevalence of *Opisthorchis viverrini* infection in Nakhon Ratchasima province, Northeast Thailand. *Asian Pac J Cancer Prev*, **13**, 5245-9.
104. Kaewpitoon SJR, R.; Ueng-Arporn, N.; Matrakool, L.; Namwichaisiriku, N.; Churproong, S.; Wongkaewpothong, P.; Nimkuntod, P.; Sripa, B.; Kaewpitoon, N. (2012). Community-based cross-sectional study of carcinogenic human liver fluke in elderly from Surin province, Thailand. *Asian Pac J Cancer Prev*, **13**, 4285-8.
105. Kamlua S, Patrakitkomjorn S, Jearanaikoon P, et al (2012). A novel TFF2 splice variant (EX2TFF2) correlates with longer overall survival time in cholangiocarcinoma. *Oncology Reports*, **27**, 1207-12.
106. Kamsa-ard S, Laopaiboon M, Luvira V, et al (2013). Association between praziquantel and cholangiocarcinoma in patients infected with *Opisthorchis viverrini*: a systematic review and meta-analysis. *Asian Pac J Cancer Prev*, **14**, 7011-6.

107. Kamsa-Ard S, Luvira V, Pugkhem A, et al (2015). Association between praziquantel treatment and cholangiocarcinoma: a hospital-based matched case-control study. *BMC Cancer*, **15**, 776.
108. Kamsa-ard S, Wiangnon S, Suwanrungruang K, et al (2011). Trends in liver cancer incidence between 1985 and 2009, Khon Kaen, Thailand: cholangiocarcinoma. *Asian Pac J Cancer Prev*, **12**, 2209-13.
109. Keeratichamroen S, Leelawat K, Thongtawee T, et al (2011). Expression of CD24 in cholangiocarcinoma cells is associated with disease progression and reduced patient survival. *Int J Oncol*, **39**, 873-81.
110. Khaenam P, Niibori A, Okada S, et al (2012). Contribution of RIZ1 to regulation of proliferation and migration of a liver fluke-related cholangiocarcinoma cell. *Asian Pac J Cancer Prev*, **13**, 4007-11.
111. Khansaard W, Techasen A, Namwat N, et al (2014). Increased EphB2 expression predicts cholangiocarcinoma metastasis. *Tumour Biol*, **35**, 10031-41.
112. Khenjanta C, Thanan R, Jusakul A, et al (2014). Association of CYP39A1, RUNX2 and oxidized alpha-1 antitrypsin expression in relation to cholangiocarcinoma progression. *Asian Pac J Cancer Prev*, **15**, 10187-92.
113. Khongmanee A, Lirdprapamongkol K, Tit-oon P, et al (2013). Proteomic analysis reveals important role of 14-3-3sigma in anoikis resistance of cholangiocarcinoma cells. *Proteomics*, **13**, 3157-66.
114. Khoontawad J, Hongsrichan N, Chamgramol Y, et al (2014). Increase of exostosin 1 in plasma as a potential biomarker for opisthorchiasis-associated cholangiocarcinoma. *Tumour Biol*, **35**, 1029-39.

115. Khoontawad J, Wongkham C, Hiraku Y, et al (2010). Proteomic identification of peroxiredoxin 6 for host defence against *Opisthorchis viverrini* infection. *Parasite Immunol*, **32**, 314-23.
116. Khunluck T, Kukongviriyapan V, Puapairoj A, et al (2014). Association of NRF2 polymorphism with cholangiocarcinoma prognosis in Thai patients. *Asian Pac J Cancer Prev*, **15**, 299-304.
117. Khuntikeo N, Chamadol N, Yongvanit P, et al (2015). Cohort profile: cholangiocarcinoma screening and care program (CASCAP). *BMC Cancer*, **15**, 459.
118. Khuntikeo N, Pugkhem A, Titapun A, et al (2014). Surgical management of perihilar cholangiocarcinoma: a Khon Kaen experience. *Journal of Hepato-biliary-pancreatic Sciences*, **21**, 521-4.
119. Kiatsopit N, Sithithaworn P, Boonmars T, et al (2011). Genetic markers for studies on the systematics and population genetics of snails, *Bithynia* spp., the first intermediate hosts of *Opisthorchis viverrini* in Thailand. *Acta Trop*, **118**, 136-41.
120. Kiatsopit N, Sithithaworn P, Kopolrat K, et al (2014). Seasonal cercarial emergence patterns of *Opisthorchis viverrini* infecting *Bithynia siamensis goniomphalos* from Vientiane Province, Lao PDR. *Parasit Vectors*, **7**, 551.
121. Kiatsopit N, Sithithaworn P, Saijuntha W, et al (2013). *Opisthorchis viverrini*: Implications of the systematics of first intermediate hosts, *Bithynia* snail species in Thailand and Lao PDR. *Infect Genet Evol*, **14**, 313-9.
122. Kidoikhammouan S, Seubwai W, Tantapotinan N, et al (2012). TNP-470, a methionine aminopeptidase-2 inhibitor, inhibits cell proliferation, migration and invasion of human cholangiocarcinoma cells in vitro. *Asian Pac J Cancer Prev*, **13 Suppl**, 155-60.

123. Kim DH, Choi DW, Choi SH, et al (2015). Is there a role for systematic hepatic pedicle lymphadenectomy in intrahepatic cholangiocarcinoma? A review of 17 years of experience in a tertiary institution. *Surgery*, **157**, 666-75.
124. Kitkumthorn N, Tuangsintanakul T, Rattanatanyong P, et al (2012). LINE-1 methylation in the peripheral blood mononuclear cells of cancer patients. *Clin Chim Acta*, **413**, 869-74.
125. Kongpetch S, Jusakul A, Ong CK, et al (2015). Pathogenesis of cholangiocarcinoma: From genetics to signalling pathways. *Best Pract Res Clin Gastroenterol*, **29**, 233-44.
126. Kongpetch S, Kukongviriyapan V, Prawan A, et al (2012). Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. *PLoS One*, **7**, e34994.
127. Kosriwong K, Menheniott TR, Giraud AS, et al (2011). Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma. *World J Gastroenterol*, **17**, 1631-41.
128. Kotawong K, Thitapakorn V, Roytrakul S, et al (2015). Plasma phosphoproteome and differential plasma phosphoproteins with opisthorchis viverrini-related cholangiocarcinoma. *Asian Pac J Cancer Prev*, **16**, 1011-8.
129. Kow AW, Wook CD, Song SC, et al (2012). Role of caudate lobectomy in type III A and III B hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. *World J Surg*, **36**, 1112-21.
130. Kraiklang R, Pairojkul C, Khuntikeo N, et al (2014). A novel predictive equation for potential diagnosis of cholangiocarcinoma. *PLoS One*, **9**, e89337.
131. Kukongviriyapan V (2012). Genetic polymorphism of drug metabolizing enzymes in association with risk of bile duct cancer. *Asian Pac J Cancer Prev*, **13 Suppl**, 7-15.



132. Kunlabut K, Vaeteewoottacharn K, Wongkham C, et al (2012). Aberrant expression of CD44 in bile duct cancer correlates with poor prognosis. *Asian Pac J Cancer Prev*, **13 Suppl**, 95-9.
133. Landskron G, De la Fuente M, Thuwajit P, et al (2014). Chronic inflammation and cytokines in the tumor microenvironment. *J Immunol Res*, **2014**, 149185.
134. Laoprom N, Sithithaworn P, Ando K, et al (2010). Microsatellite loci in the carcinogenic liver fluke, *Opisthorchis viverrini* and their application as population genetic markers. *Infection, Genetics & Evolution*, **10**, 146-53.
135. Laothong U, Hiraku Y, Oikawa S, et al (2015). Melatonin induces apoptosis in cholangiocarcinoma cell lines by activating the reactive oxygen species-mediated mitochondrial pathway. *Oncol Rep*, **33**, 1443-9.
136. Laothong U, Pinlaor P, Boonsiri P, et al (2013). Melatonin inhibits cholangiocarcinoma and reduces liver injury in *Opisthorchis viverrini*-infected and N-nitrosodimethylamine-treated hamsters. *J Pineal Res*, **55**, 257-66.
137. Laothong U, Pinlaor P, Hiraku Y, et al (2010). Protective effect of melatonin against *Opisthorchis viverrini*-induced oxidative and nitrosative DNA damage and liver injury in hamsters. *J Pineal Res*, **49**, 271-82.
138. Larbcharoensub N, Sornmayura P, Sirachainan E, et al (2011). Prognostic value of ABCG2 in moderately and poorly differentiated intrahepatic cholangiocarcinoma. *Histopathology*, **59**, 235-46.
139. Lee SY, Cherqui D (2013). Operative management of cholangiocarcinoma. *Semin Liver Dis*, **33**, 248-61.
140. Leelawat K, Narong S, Wannaprasert J, et al (2011a). Serum NGAL to Clinically Distinguish Cholangiocarcinoma from Benign Biliary Tract Diseases. *Int J Hepatol*, **2011**, 873548.

141. Leelawat K, Narong S, Wannaprasert J, et al (2010a). Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. *World Journal of Gastroenterology*, **16**, 4697-703.
142. Leelawat K, Thongtawee T, Narong S, et al (2011b). Strong expression of CD133 is associated with increased cholangiocarcinoma progression. *World J Gastroenterol*, **17**, 1192-8.
143. Leelawat K, Udomchaiprasertkul W, Narong S, et al (2010b). Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells. *J Cancer Res Clin Oncol*, **136**, 1537-44.
144. Leelawat S, Leelawat K, Narong S, et al (2010c). The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration. *Cancer Invest*, **28**, 357-63.
145. Lekphrom R, Kanokmedhakul S, Kukongviriyapan V, et al (2011). C-7 oxygenated coumarins from the fruits of *Micromelum minutum*. *Arch Pharm Res*, **34**, 527-31.
146. Limpai boon T (2012). Epigenetic aberrations in cholangiocarcinoma: potential biomarkers and promising target for novel therapeutic strategies. *Asian Pac J Cancer Prev*, **13 Suppl**, 41-5.
147. Loilome W, Bungkanjana P, Techasen A, et al (2014). Activated macrophages promote Wnt/beta-catenin signaling in cholangiocarcinoma cells. *Tumour Biol*, **35**, 5357-67.
148. Loilome W, Juntana S, Namwat N, et al (2011). PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. *Int J Cancer*, **129**, 34-44.
149. Loilome W, Juntana S, Pinitsoontorn C, et al (2012a). Suppression of PRKAR1A expression enhances anti-proliferative and apoptotic effects of protein kinase inhibitors

and chemotherapeutic drugs on cholangiocarcinoma cells. *Asian Pac J Cancer Prev*, **13 Suppl**, 143-7.

150. Loilome W, Kadsanit S, Namwat N, et al (2012b). Impaired antioxidant enzyme activity and increased DNA repair enzyme expression in hamster liver tissues related to cholangiocarcinoma development. *Asian Pac J Cancer Prev*, **13 Suppl**, 59-64.
151. Loilome W, Wechagama P, Namwat N, et al (2012c). Expression of oxysterol binding protein isoforms in opisthorchiasis-associated cholangiocarcinoma: a potential molecular marker for tumor metastasis. *Parasitol Int*, **61**, 136-9.
152. Loilome W, Yooyuen S, Namwat N, et al (2012d). PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group. *Tumour Biol*, **33**, 2289-98.
153. Lozada ME, Chaiteerakij R, Roberts LR (2015). Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging? *Curr Hepatol Rep*, **14**, 128-38.
154. Mahavorasirikul W, Viyanant V, Chaijaroenkul W, et al (2010). Cytotoxic activity of Thai medicinal plants against human cholangiocarcinoma, laryngeal and hepatocarcinoma cells in vitro. *BMC Complement Altern Med*, **10**, 55.
155. Mairiang E, Laha T, Bethony JM, et al (2012). Ultrasonography assessment of hepatobiliary abnormalities in 3359 subjects with *Opisthorchis viverrini* infection in endemic areas of Thailand. *Parasitol Int*, **61**, 208-11.
156. Maksimova GA, Pakharukova MY, Kashina EV, et al (2015). Effect of *Opisthorchis felinus* infection and dimethylnitrosamine administration on the induction of cholangiocarcinoma in Syrian hamsters. *Parasitol Int*.

157. Manwong M, Songserm N, Promthet S, et al (2013). Risk factors for cholangiocarcinoma in the lower part of Northeast Thailand: a hospital-based case-control study. *Asian Pac J Cancer Prev*, **14**, 5953-6.
158. Matchimakul P, Rinaldi G, Suttiprapa S, et al (2015). Apoptosis of cholangiocytes modulated by thioredoxin of carcinogenic liver fluke. *Int J Biochem Cell Biol*, **65**, 72-80.
159. Mathema VB, Na-Bangchang K (2015). Current insights on cholangiocarcinoma research: a brief review. *Asian Pac J Cancer Prev*, **16**, 1307-13.
160. Matsuda A, Kuno A, Nakagawa T, et al (2015). Lectin Microarray-Based Sero-Biomarker Verification Targeting Aberrant O-Linked Glycosylation on Mucin 1. *Anal Chem*, **87**, 7274-81.
161. Menakongka A, Suthiphongchai T (2010). Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion. *World J Gastroenterol*, **16**, 713-22.
162. Monsouvanh A, Proungvitaya T, Limpai boon T, et al (2014). Serum cathepsin B to cystatin C ratio as a potential marker for the diagnosis of cholangiocarcinoma. *Asian Pac J Cancer Prev*, **15**, 9511-5.
163. Moolthiya P, Tohtong R, Keeratichamroen S, et al (2014). Role of mTOR inhibitor in cholangiocarcinoma cell progression. *Oncol Lett*, **7**, 854-60.
164. Moonsom S, Tayapiwatana C, Wongkham S, et al (2010). A Competitive ELISA for quantifying serum CD147: reduction of soluble CD147 levels in cancer patient sera. *Hybridoma (Larchmt)*, **29**, 45-52.
165. Muisuk K, Silsirivanit A, Imtawil K, et al (2015). Novel mutations in cholangiocarcinoma with low frequencies revealed by whole mitochondrial genome sequencing. *Asian Pac J Cancer Prev*, **16**, 1737-42.

166. Mulvenna J, Sripa B, Brindley PJ, et al (2010). The secreted and surface proteomes of the adult stage of the carcinogenic human liver fluke *Opisthorchis viverrini*. *Proteomics*, **10**, 1063-78.
167. Mulvenna J, Yonglitthipagon P, Sripa B, et al (2012). Banking on the future: biobanking for "omics" approaches to biomarker discovery for *Opisthorchis*-induced cholangiocarcinoma in Thailand. *Parasitology International*, **61**, 173-7.
168. Na-Bangchang K, Karbwang J (2014). Traditional herbal medicine for the control of tropical diseases. *Trop Med Health*, **42**, 3-13.
169. Namsanor JS, P.; Kopolrat, K.; Kiatsopit, N.; Pitaksakulrat, O.; Tesana, S.; Andrews, R. H.; Petney, T. N. (2015). Seasonal transmission of *Opisthorchis viverrini* sensu lato and a lecithodendriid trematode species in *Bithynia siamensis* goniomphalos snails in northeast Thailand. *Am J Trop Med Hyg*, **93**, 87-93.
170. Namwat N, Chusorn P, Loilome W, et al (2012). Expression profiles of oncomir miR-21 and tumor suppressor let-7a in the progression of opisthorchiasis-associated cholangiocarcinoma. *Asian Pac J Cancer Prev*, **13 Suppl**, 65-9.
171. Namwat N, Puetkasichonpasutha J, Loilome W, et al (2011). Downregulation of reversion-inducing-cysteine-rich protein with Kazal motifs (RECK) is associated with enhanced expression of matrix metalloproteinases and cholangiocarcinoma metastases. *J Gastroenterol*, **46**, 664-75.
172. Nateewattana J, Dutta S, Reabroi S, et al (2014). Induction of apoptosis in cholangiocarcinoma by an andrographolide analogue is mediated through topoisomerase II alpha inhibition. *Eur J Pharmacol*, **723**, 148-55.
173. Nguyen TG, Le TH, De NV, et al (2010). Assessment of a 27-kDa antigen in enzyme-linked immunosorbent assay for the diagnosis of fasciolosis in Vietnamese patients. *Trop Med Int Health*, **15**, 462-7.

174. Ninlawan K, O'Hara SP, Splinter PL, et al (2010). Opisthorchis viverrini excretory/secretory products induce toll-like receptor 4 upregulation and production of interleukin 6 and 8 in cholangiocyte. *Parasitol Int*, **59**, 616-21.
175. Nitta T, Nakanuma Y, Sato Y, et al (2015). Pathological characteristics of intraductal polypoid neoplasms of bile ducts in Thailand. *Int J Clin Exp Pathol*, **8**, 8284-90.
176. Nuntagawat C, Leelawat K, Tohtong R (2010). NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. *Clin Exp Metastasis*, **27**, 295-305.
177. Nutthasirikul N, Hahnvajjanawong C, Techasen A, et al (2015). Targeting the 133p53 isoform can restore chemosensitivity in 5-fluorouracil-resistant cholangiocarcinoma cells. *Int J Oncol*, **47**, 2153-64.
178. Nutthasirikul N, Limpaboon T, Leelayuwat C, et al (2013). Ratio disruption of the 133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma. *Int J Oncol*, **42**, 1181-8.
179. Obchoei S, Sawanyawisuth K, Wongkham C, et al (2015). Secreted cyclophilin A mediates G1/S phase transition of cholangiocarcinoma cells via CD147/ERK1/2 pathway. *Tumour Biol*, **36**, 849-59.
180. Ong CK, Subimerb C, Pairojkul C, et al (2012). Exome sequencing of liver fluke-associated cholangiocarcinoma. *Nat Genet*, **44**, 690-3.
181. Paholpak P, Sirichativapee W, Wisanuyotin T, et al (2012). Prevalence of known and unknown primary tumor sites in spinal metastasis patients. *Open Orthop J*, **6**, 440-4.
182. Pakharukova MY, Vavilin VA, Sripa B, et al (2015). Functional Analysis of the Unique Cytochrome P450 of the Liver Fluke Opisthorchis felineus. *PLoS Negl Trop Dis*, **9**, e0004258.

183. Panpimanmas S, Ratanachu-ek T (2013). Endoscopic ultrasound-guided hepaticogastrostomy for advanced cholangiocarcinoma after failed stenting by endoscopic retrograde cholangiopancreatography. *Asian J Surg*, **36**, 154-8.
184. Papatpremsiri A, Smout MJ, Loukas A, et al (2015). Suppression of Ov-grn-1 encoding granulin of *Opisthorchis viverrini* inhibits proliferation of biliary epithelial cells. *Exp Parasitol*, **148**, 17-23.
185. Pattanapairoj S, Silsirivanit A, Muisuk K, et al (2015). Improve discrimination power of serum markers for diagnosis of cholangiocarcinoma using data mining-based approach. *Clin Biochem*, **48**, 668-73.
186. Pattanathien P, Khuntikeo N, Promthet S, et al (2013). Survival rate of extrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. *Asian Pac J Cancer Prev*, **14**, 321-4.
187. Peng J, Feng Y, Rinaldi G, et al (2014). The miRNAome of *Opisthorchis viverrini* induced intrahepatic cholangiocarcinoma. *Genom Data*, **2**, 274-9.
188. Petney T, Sithithaworn P, Andrews R, et al (2012). The ecology of the Bithynia first intermediate hosts of *Opisthorchis viverrini*. *Parasitol Int*, **61**, 38-45.
189. Petrick JL, Sahasrabudhe VV, Chan AT, et al (2015). NSAID Use and Risk of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: The Liver Cancer Pooling Project. *Cancer Prev Res (Phila)*, **8**, 1156-62.
190. Phoomak C, Silsirivanit A, Wongkham C, et al (2012). Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma. *Asian Pac J Cancer Prev*, **13 Suppl**, 101-5.
191. Phumyen A, Jantasorn S, Jumnainsong A, et al (2014). Doxorubicin-conjugated bacteriophages carrying anti-MHC class I chain-related A for targeted cancer therapy in vitro. *Onco Targets Ther*, **7**, 2183-95.

192. Pingaew R, Prachayasittikul S, Ruchirawat S, et al (2013). Synthesis and structure-activity relationship of mono-indole-, bis-indole-, and tris-indole-based sulfonamides as potential anticancer agents. *Mol Divers*, **17**, 595-604.
193. Pinlaor P, Pongsamart P, Hongsrirachan N, et al (2012). Specific serum IgG, but not IgA, antibody against purified *Opisthorchis viverrini* antigen associated with hepatobiliary disease and cholangiocarcinoma. *Parasitol Int*, **61**, 212-6.
194. Pinlaor S, Onsurathum S, Boonmars T, et al (2013). Distribution and abundance of *Opisthorchis viverrini* metacercariae in cyprinid fish in Northeastern Thailand. *Korean J Parasitol*, **51**, 703-10.
195. Pinlaor S, Prakobwong S, Hiraku Y, et al (2010). Reduction of periductal fibrosis in liver fluke-infected hamsters after long-term curcumin treatment. *Eur J Pharmacol*, **638**, 134-41.
196. Piratae S (2015). *Bithynia siamensis* goniomphalos, the first intermediate host of *Opisthorchis viverrini* in Thailand. *Asian Pac J Trop Med*, **8**, 779-83.
197. Piratae S, Tesana S, Jones MK, et al (2012). Molecular characterization of a tetraspanin from the human liver fluke, *Opisthorchis viverrini*. *PLoS Negl Trop Dis*, **6**, e1939.
198. Pitaksakulrat OS, P.; Laoprom, N.; Laha, T.; Petney, T. N.; Andrews, R. H. (2013). A cross-sectional study on the potential transmission of the carcinogenic liver fluke *Opisthorchis viverrini* and other fishborne zoonotic trematodes by aquaculture fish. *Foodborne Pathog Dis*, **10**, 35-41.
199. Plengsuriyakarn T, Eursitthichai V, Labunruang N, et al (2012a). Ultrasonography as a tool for monitoring the development and progression of cholangiocarcinoma in *Opisthorchis viverrini*/ dimethylnitrosamine-induced hamsters. *Asian Pac J Cancer Prev*, **13**, 87-90.



200. Plengsuriyakarn T, Karbwang J, Na-Bangchang K (2015a). Anticancer activity using positron emission tomography-computed tomography and pharmacokinetics of beta-eudesmol in human cholangiocarcinoma xenografted nude mouse model. *Clin Exp Pharmacol Physiol*, **42**, 293-304.
201. Plengsuriyakarn T, Matsuda N, Karbwang J, et al (2015b). Anticancer Activity of *Atractylodes lancea* (Thunb.) DC in a Hamster Model and Application of PET-CT for Early Detection and Monitoring Progression of Cholangiocarcinoma. *Asian Pac J Cancer Prev*, **16**, 6279-84.
202. Plengsuriyakarn T, Viyanant V, Eursitthichai V, et al (2012b). Anticancer activities against cholangiocarcinoma, toxicity and pharmacological activities of Thai medicinal plants in animal models. *BMC Complement Altern Med*, **12**, 23.
203. Plengsuriyakarn T, Viyanant V, Eursitthichai V, et al (2012c). Cytotoxicity, toxicity, and anticancer activity of *Zingiber officinale* Roscoe against cholangiocarcinoma. *Asian Pac J Cancer Prev*, **13**, 4597-606.
204. Plieskatt J, Rinaldi G, Feng Y, et al (2015). A microRNA profile associated with *Opisthorchis viverrini*-induced cholangiocarcinoma in tissue and plasma. *BMC Cancer*, **15**, 309.
205. Plieskatt JL, Rinaldi G, Feng Y, et al (2014). Distinct miRNA signatures associate with subtypes of cholangiocarcinoma from infection with the tumourigenic liver fluke *Opisthorchis viverrini*. *J Hepatol*, **61**, 850-8.
206. Pongcharoen P, Jinawath A, Tohtong R (2011). Silencing of CD44 by siRNA suppressed invasion, migration and adhesion to matrix, but not secretion of MMPs, of cholangiocarcinoma cells. *Clin Exp Metastasis*, **28**, 827-39.

207. Prachayakul V, Aswakul P (2012). Successful endoscopic treatment of iatrogenic biloma as a complication of endosonography-guided hepaticogastrostomy: The first case report. *J Interv Gastroenterol*, **2**, 202-4.
208. Prachayakul V, Chaisayan S, Aswakul P, et al (2013). Clinical characteristics and treatment outcomes of patients with unresectable cholangiocarcinoma in Thailand: are there differences dependent on stent type? *Asian Pac J Cancer Prev*, **14**, 529-32.
209. Prakobwong S, Charoensuk L, Hiraku Y, et al (2012a). Plasma hydroxyproline, MMP-7 and collagen I as novel predictive risk markers of hepatobiliary disease-associated cholangiocarcinoma. *Int J Cancer*, **131**, E416-24.
210. Prakobwong S, Gupta SC, Kim JH, et al (2011a). Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. *Carcinogenesis*, **32**, 1372-80.
211. Prakobwong S, Khoontawad J, Yongvanit P, et al (2011b). Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. *Int J Cancer*, **129**, 88-100.
212. Prakobwong S, Pinlaor P, Charoensuk L, et al (2012b). The liver fluke *Opisthorchis viverrini* expresses nitric oxide synthase but not gelatinases. *Parasitol Int*, **61**, 112-7.
213. Prakobwong S, Yongvanit P, Hiraku Y, et al (2010). Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model. *Int J Cancer*, **127**, 2576-87.
214. Prasongwatana J, Laummaunwai P, Boonmars T, et al (2013). Viable metacercariae of *Opisthorchis viverrini* in northeastern Thai cyprinid fish dishes--as part of a rational program for control of *O. viverrini*-associated cholangiocarcinoma. *Parasitol Res*, **112**, 1323-7.

215. Prasopdee S, Sotillo J, Tesana S, et al (2014). RNA-Seq reveals infection-induced gene expression changes in the snail intermediate host of the carcinogenic liver fluke, *Opisthorchis viverrini*. *PLoS Negl Trop Dis*, **8**, e2765.
216. Prasopdee S, Tesana S, Cantacessi C, et al (2015). Proteomic profile of *Bithynia siamensis* goniomphalos snails upon infection with the carcinogenic liver fluke *Opisthorchis viverrini*. *J Proteomics*, **113**, 281-91.
217. Pua U, Quek LH (2013). Modified retroperitoneal access for percutaneous intervention after pancreaticoduodenectomy. *Korean J Radiol*, **14**, 446-50.
218. Puthdee N, Vaeteewoottacharn K, Seubwai W, et al (2013). Establishment of an allo-transplantable hamster cholangiocarcinoma cell line and its application for in vivo screening of anti-cancer drugs. *Korean J Parasitol*, **51**, 711-7.
219. Rattanasing W, Kaewpitoon SJ, Loyd RA, et al (2015). Utilization of Google Earth for Distribution Mapping of Cholangiocarcinoma: a Case Study in Satuek District, Buriram, Thailand. *Asian Pac J Cancer Prev*, **16**, 5903-6.
220. Rattanata N, Daduang S, Wongwattanakul M, et al (2015). Gold Nanoparticles Enhance the Anticancer Activity of Gallic Acid against Cholangiocarcinoma Cell Lines. *Asian Pac J Cancer Prev*, **16**, 7143-7.
221. Rerknimitr R, Angsuwatcharakon P, Ratanachu-ek T, et al (2013). Asia-Pacific consensus recommendations for endoscopic and interventional management of hilar cholangiocarcinoma. *J Gastroenterol Hepatol*, **28**, 593-607.
222. Ridthitid W, Rerknimitr R, Janchai A, et al (2010). Outcome of second interventions for occluded metallic stents in patients with malignant biliary obstruction. *Surg Endosc*, **24**, 2216-20.

223. Rucksaken R, Haonon O, Pinlaor P, et al (2015). Plasma IgG autoantibody against actin-related protein 3 in liver fluke *Opisthorchis viverrini* infection. *Parasite Immunol*, **37**, 340-8.
224. Rucksaken R, Khoontawad J, Roytrakul S, et al (2012). Proteomic analysis to identify plasma orosomucoid 2 and kinesin 18A as potential biomarkers of cholangiocarcinoma. *Cancer Biomark*, **12**, 81-95.
225. Rucksaken R, Pairojkul C, Pinlaor P, et al (2014). Plasma autoantibodies against heat shock protein 70, enolase 1 and ribonuclease/angiogenin inhibitor 1 as potential biomarkers for cholangiocarcinoma. *PLoS One*, **9**, e103259.
226. Rungsakulkij N, Boonsakan P (2014). Synchronous gallbladder and pancreatic cancer associated with pancreaticobiliary maljunction. *World J Gastroenterol*, **20**, 14500-4.
227. Saengboonmee C, Seubwai W, Wongkham C, et al (2015). Diabetes mellitus: Possible risk and promoting factors of cholangiocarcinoma: Association of diabetes mellitus and cholangiocarcinoma. *Cancer Epidemiol*, **39**, 274-8.
228. Saengsawang P, Promthet S, Bradshaw P (2013). Infection with *Opisthorchis viverrini* and use of praziquantel among a working-age population in northeast Thailand. *Asian Pac J Cancer Prev*, **14**, 2963-6.
229. Saengsawang PP, S.; Bradshaw, P. (2012). Prevalence of OV infection in Yasothon Province, Northeast Thailand. *Asian Pac J Cancer Prev*, **13**, 3399-402.
230. Saichua P, Sithithaworn P, Jariwala AR, et al (2013). Microproteinuria during *Opisthorchis viverrini* infection: a biomarker for advanced renal and hepatobiliary pathologies from chronic opisthorchiasis. *PLoS Negl Trop Dis*, **7**, e2228.
231. Saichua P, Yakovleva A, Kamamia C, et al (2015). Levels of 8-OxodG Predict Hepatobiliary Pathology in *Opisthorchis viverrini* Endemic Settings in Thailand. *PLoS Negl Trop Dis*, **9**, e0003949.

232. Samatiwat P, Prawan A, Senggunprai L, et al (2015). Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells. *Naunyn Schmiedebergs Arch Pharmacol*, **388**, 601-12.
233. Sangchan A, Kongkasame W, Pugkhem A, et al (2012). Efficacy of metal and plastic stents in unresectable complex hilar cholangiocarcinoma: a randomized controlled trial. *Gastrointest Endosc*, **76**, 93-9.
234. Sawangsoda P, Sithithaworn J, Tesana S, et al (2012). Diagnostic values of parasite-specific antibody detections in saliva and urine in comparison with serum in opisthorchiasis. *Parasitol Int*, **61**, 196-202.
235. Sawanyawisuth K, Silsirivanit A, Kunlabut K, et al (2012a). A novel carbohydrate antigen expression during development of *Opisthorchis viverrini*- associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis. *Parasitol Int*, **61**, 151-4.
236. Sawanyawisuth K, Wongkham C, Araki N, et al (2012b). Serial analysis of gene expression reveals promising therapeutic targets for liver fluke-associated cholangiocarcinoma. *Asian Pac J Cancer Prev*, **13 Suppl**, 89-93.
237. Sawanyawisuth K, Wongkham C, Riggins GJ, et al (2012c). Possible involvement of cyclophilin A processing in fumagillin-induced suppression of cholangiocarcinoma cell proliferation. *Asian Pac J Cancer Prev*, **13 Suppl**, 137-41.
238. Seeree P, Pearngam P, Kumkate S, et al (2015). An Omics Perspective on Molecular Biomarkers for Diagnosis, Prognosis, and Therapeutics of Cholangiocarcinoma. *Int J Genomics*, **2015**, 179528.
239. Senggunprai L, Kukongviriyapan V, Prawan A, et al (2014). Quercetin and EGCG exhibit chemopreventive effects in cholangiocarcinoma cells via suppression of JAK/STAT signaling pathway. *Phytother Res*, **28**, 841-8.

240. Seubwai W, Kraiklang R, Wongkham C, et al (2012). Hypoxia enhances aggressiveness of cholangiocarcinoma cells. *Asian Pac J Cancer Prev*, **13 Suppl**, 53-8.
241. Seubwai W, Vaeteewoottacharn K, Hiyoshi M, et al (2010a). Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB. *Cancer Sci*, **101**, 1590-5.
242. Seubwai W, Wongkham C, Puapairoj A, et al (2014). Aberrant expression of NF-kappaB in liver fluke associated cholangiocarcinoma: implications for targeted therapy. *PLoS One*, **9**, e106056.
243. Seubwai W, Wongkham C, Puapairoj A, et al (2010b). 22-oxa-1,25-dihydroxyvitamin D3 efficiently inhibits tumor growth in inoculated mice and primary histoculture of cholangiocarcinoma. *Cancer*, **116**, 5535-43.
244. Shin HR, Oh JK, Masuyer E, et al (2010). Epidemiology of cholangiocarcinoma: an update focusing on risk factors. *Cancer Sci*, **101**, 579-85.
245. Silakit R, Loilome W, Yongvanit P, et al (2014). Circulating miR-192 in liver fluke-associated cholangiocarcinoma patients: a prospective prognostic indicator. *J Hepatobiliary Pancreat Sci*, **21**, 864-72.
246. Silakit R, Loilome W, Yongvanit P, et al (2015). Urinary microRNA-192 and microRNA-21 as potential indicators for liver fluke-associated cholangiocarcinoma risk group. *Parasitol Int*.
247. Silsirivanit A, Araki N, Wongkham C, et al (2011). A novel serum carbohydrate marker on mucin 5AC: values for diagnostic and prognostic indicators for cholangiocarcinoma. *Cancer*, **117**, 3393-403.
248. Silsirivanit A, Araki N, Wongkham C, et al (2013). CA-S27: a novel Lewis a associated carbohydrate epitope is diagnostic and prognostic for cholangiocarcinoma. *Cancer Sci*, **104**, 1278-84.

249. Silsirivanit A, Sawanyawisuth K, Riggins GJ, et al (2014). Cancer biomarker discovery for cholangiocarcinoma: the high-throughput approaches. *J Hepatobiliary Pancreat Sci*, **21**, 388-96.
250. Sithithaworn P, Andrews RH, Nguyen VD, et al (2012a). The current status of opisthorchiasis and clonorchiasis in the Mekong Basin. *Parasitol Int*, **61**, 10-6.
251. Sithithaworn P, Andrews RH, Petney TN, et al (2012b). The systematics and population genetics of *Opisthorchis viverrini* sensu lato: implications in parasite epidemiology and bile duct cancer. *Parasitol Int*, **61**, 32-7.
252. Sithithaworn P, Petney TN, Andrews RH (2015). What significance do helminths species-complexes have for the prevention, diagnosis and treatment of human infections? *Trans R Soc Trop Med Hyg*, **109**, 289-90.
253. Sithithaworn PY, P.; Duengai, K.; Kiatsopit, N.; Pairojkul, C. (2014). Roles of liver fluke infection as risk factor for cholangiocarcinoma. *J Hepatobiliary Pancreat Sci*, **21**, 301-8.
254. Smout MJ, Sotillo J, Laha T, et al (2015). Carcinogenic Parasite Secretes Growth Factor That Accelerates Wound Healing and Potentially Promotes Neoplasia. *PLoS Pathog*, **11**, e1005209.
255. Sombattheera S, Prongvitaya T, Limpai boon T, et al (2015). Total serum bile acid as a potential marker for the diagnosis of cholangiocarcinoma without jaundice. *Asian Pac J Cancer Prev*, **16**, 1367-70.
256. Songserm N, Promthet S, Sithithaworn P, et al (2012). Risk factors for cholangiocarcinoma in high-risk area of Thailand: role of lifestyle, diet and methylenetetrahydrofolate reductase polymorphisms. *Cancer Epidemiol*, **36**, e89-94.
257. Songserm NP, S.; Pientong, C.; Ekalaksananan, T.; Chopjitt, P.; Wiangnon, S. (2014). Gene-environment interaction involved in cholangiocarcinoma in the Thai population:

- polymorphisms of DNA repair genes, smoking and use of alcohol. *BMJ Open*, **4**, e005447.
258. Songserm NP, S.; Sithithaworn, P.; Pientong, C.; Ekalaksananan, T.; Chopjitt, P.; Parkin, D. M. (2011). MTHFR polymorphisms and *Opisthorchis viverrini* infection: a relationship with increased susceptibility to cholangiocarcinoma in Thailand. *Asian Pac J Cancer Prev*, **12**, 1341-5.
259. Songserm NP, S.; Wiangnon, S.; Sithithaworn, P. (2012). Prevalence and co-infection of intestinal parasites among Thai rural residents at high-risk of developing cholangiocarcinoma: a cross-sectional study in a prospective cohort study. *Asian Pac J Cancer Prev*, **13**, 6175-9.
260. Songsiang U, Pitchuanom S, Boonyarat C, et al (2010). Cytotoxicity against cholangiocarcinoma cell lines of zerumbone derivatives. *Eur J Med Chem*, **45**, 3794-802.
261. Sookprasert A, Chindaprasert J, Wirasorn K (2012a). Systemic therapy for locally advanced and metastatic cholangiocarcinoma. *Asian Pac J Cancer Prev*, **13 Suppl**, 3-6.
262. Sookprasert A, Pugkhem A, Khuntikeo N, et al (2012b). Evaluation of efficacy, safety and tolerability of high dose-intermittent calcitriol supplementation to advanced intrahepatic cholangiocarcinoma patients--a pilot study. *Asian Pac J Cancer Prev*, **13 Suppl**, 161-7.
263. Srimunta U, Sawanyawisuth K, Kraiklang R, et al (2012). High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma. *Asian Pac J Cancer Prev*, **13 Suppl**, 125-30.
264. Sripa B, Bethony JM, Sithithaworn P, et al (2011a). Opisthorchiasis and Opisthorchis-associated cholangiocarcinoma in Thailand and Laos. *Acta Trop*, **120 Suppl 1**, S158-68.



265. Sripa B, Brindley PJ, Mulvenna J, et al (2012a). The tumorigenic liver fluke *Opisthorchis viverrini*--multiple pathways to cancer. *Trends Parasitol*, **28**, 395-407.
266. Sripa B, Tangkawattana S, Laha T, et al (2015). Toward integrated opisthorchiasis control in northeast Thailand: the Lawa project. *Acta Trop*, **141**, 361-7.
267. Sripa B, Thinkhamrop B, Mairiang E, et al (2012b). Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by *Opisthorchis viverrini*. *PLoS Negl Trop Dis*, **6**, e1654.
268. Sripa J, Pinlaor P, Brindley PJ, et al (2011b). RNA interference targeting cathepsin B of the carcinogenic liver fluke, *Opisthorchis viverrini*. *Parasitol Int*, **60**, 283-8.
269. Sriputtha S, Khuntikeo N, Promthet S, et al (2013). Survival rate of intrahepatic cholangiocarcinoma patients after surgical treatment in Thailand. *Asian Pac J Cancer Prev*, **14**, 1107-10.
270. Sriraj P, Aukkanimart R, Boonmars T, et al (2013). Does a combination of opisthorchiasis and ethyl alcohol consumption enhance early cholangiofibrosis, the risk of cholangiocarcinoma? *Parasitol Res*, **112**, 2971-81.
271. Sriraksa R, Limpaboon T (2013). Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma - cell line findings. *Asian Pac J Cancer Prev*, **14**, 2503-8.
272. Sriraksa R, Limpaboon T (2015). TRAIL in Combination with Subtoxic 5-FU Effectively Inhibit Cell Proliferation and Induce Apoptosis in Cholangiocarcinoma Cells. *Asian Pac J Cancer Prev*, **16**, 6991-6.
273. Sriraksa R, Zeller C, Dai W, et al (2013). Aberrant DNA methylation at genes associated with a stem cell-like phenotype in cholangiocarcinoma tumors. *Cancer Prev Res (Phila)*, **6**, 1348-55.

274. Sriraksa R, Zeller C, El-Bahrawy MA, et al (2011). CpG-island methylation study of liver fluke-related cholangiocarcinoma. *Br J Cancer*, **104**, 1313-8.
275. Srisomsap C, Sawangareetrakul P, Subhasitanont P, et al (2010). Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. *Journal of Biomedicine & Biotechnology*, **2010**, 437143.
276. Srivatanakul PH, S.; Kittiwatanachot, P.; Jedpiyawongse, A.; Khuhaprema, T.; Miwa, M. (2010). Hepatitis viruses and risk of cholangiocarcinoma in northeast Thailand. *Asian Pac J Cancer Prev*, **11**, 985-8.
277. Sriwanitchrak P, Viyanant V, Chaijaroenkul W, et al (2011). Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma. *Asian Pac J Cancer Prev*, **12**, 1503-10.
278. Subimerb C, Pinlaor S, Khuntikeo N, et al (2010a). Tissue invasive macrophage density is correlated with prognosis in cholangiocarcinoma. *Mol Med Rep*, **3**, 597-605.
279. Subimerb C, Pinlaor S, Lulitanond V, et al (2010b). Circulating CD14(+) CD16(+) monocyte levels predict tissue invasive character of cholangiocarcinoma. *Clin Exp Immunol*, **161**, 471-9.
280. Subimerb C, Wongkham C, Khuntikeo N, et al (2014). Transcriptional profiles of peripheral blood leukocytes identify patients with cholangiocarcinoma and predict outcome. *Asian Pac J Cancer Prev*, **15**, 4217-24.
281. Subrungruanga I, Thawornkunob C, Chawalitchewinkoon-Petmitrc P, et al (2013). Gene expression profiling of intrahepatic cholangiocarcinoma. *Asian Pacific Journal of Cancer Prevention: Apjcp*, **14**, 557-63.
282. Sudsarn P, Wongchalee N, Boonmars T, et al (2014). Sex differences in opisthorchiosis and the development of cholangiocarcinoma in Syrian hamster model. *Parasitol Res*, **113**, 829-35.

283. Sumsakul W, Mahavorasirikul W, Na-Bangchang K (2015). Inhibitory Activities of Thai Medicinal Plants with Promising Activities Against Malaria and Cholangiocarcinoma on Human Cytochrome P450. *Phytother Res*, **29**, 1926-33.
284. Suphim B, Prawan A, Kukongviriyapan U, et al (2010). Redox modulation and human bile duct cancer inhibition by curcumin. *Food Chem Toxicol*, **48**, 2265-72.
285. Suriyo T, Pholphana N, Rangkadilok N, et al (2014). Andrographis paniculata extracts and major constituent diterpenoids inhibit growth of intrahepatic cholangiocarcinoma cells by inducing cell cycle arrest and apoptosis. *Planta Med*, **80**, 533-43.
286. Suthiwong J, Pitchuanom S, Wattanawongdon W, et al (2014). Terpenoids from the root bark of Pterolobium macropterum. *J Nat Prod*, **77**, 2432-7.
287. Suwannatrai AS, K.; Haruay, S.; Piratae, S.; Thammasiri, C.; Khampoosa, P.; Kulsantiwong, J.; Prasopdee, S.; Tarbsripair, P.; Suwanwerakamtorn, R.; Sukchan, S.; Boonmars, T.; Malone, J. B.; Kearney, M. T.; Tesana, S. (2011). Effect of soil surface salt on the density and distribution of the snail Bithynia siamensis goniomphalos in northeast Thailand. *Geospat Health*, **5**, 183-90.
288. Talabnin K, Aoki K, Saichua P, et al (2013). Stage-specific expression and antigenicity of glycoprotein glycans isolated from the human liver fluke, Opisthorchis viverrini. *Int J Parasitol*, **43**, 37-50.
289. Tan FL, Ooi A, Huang D, et al (2010). p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. *Int J Cancer*, **126**, 2353-61.
290. Tangkijvanich P, Chanmee T, Komtong S, et al (2010). Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. *J Gastroenterol Hepatol*, **25**, 129-37.

291. Techasen A, Loilome W, Namwat N, et al (2012a). Cytokines released from activated human macrophages induce epithelial mesenchymal transition markers of cholangiocarcinoma cells. *Asian Pac J Cancer Prev*, **13 Suppl**, 115-8.
292. Techasen A, Loilome W, Namwat N, et al (2012b). *Opisthorchis viverrini*-antigen induces expression of MARCKS during inflammation-associated cholangiocarcinogenesis. *Parasitol Int*, **61**, 140-4.
293. Techasen A, Loilome W, Namwat N, et al (2014a). Loss of E-cadherin promotes migration and invasion of cholangiocarcinoma cells and serves as a potential marker of metastasis. *Tumour Biol*, **35**, 8645-52.
294. Techasen A, Loilome W, Namwat N, et al (2010). Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway. *Cancer Sci*, **101**, 658-65.
295. Techasen A, Namwat N, Loilome W, et al (2012c). Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) stimulates the epithelial-mesenchymal transition regulator Snail in cholangiocarcinoma. *Med Oncol*, **29**, 3083-91.
296. Techasen A, Namwat N, Loilome W, et al (2014b). Tumor necrosis factor- $\alpha$  modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma progression. *J Hepatobiliary Pancreat Sci*, **21**, 703-11.
297. Teo JY, Allen JC, Jr., Ng DC, et al (2015). A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90. *HPB (Oxford)*.
298. Thanan R, Oikawa S, Hiraku Y, et al (2015a). Oxidative stress and its significant roles in neurodegenerative diseases and cancer. *Int J Mol Sci*, **16**, 193-217.

299. Thanan R, Pairojkul C, Pinlaor S, et al (2013). Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. *Free Radic Biol Med*, **65**, 1464-72.
300. Thanan R, Techasen A, Hou B, et al (2015b). Development and characterization of a hydrogen peroxide-resistant cholangiocyte cell line: A novel model of oxidative stress-related cholangiocarcinoma genesis. *Biochem Biophys Res Commun*, **464**, 182-8.
301. Thanasai J, Limpaboon T, Jearanaikoon P, et al (2010). Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. *World J Gastroenterol*, **16**, 1631-8.
302. Thanasuwan S, Piratae S, Brindley PJ, et al (2014). Suppression of aquaporin, a mediator of water channel control in the carcinogenic liver fluke, *Opisthorchis viverrini*. *Parasit Vectors*, **7**, 224.
303. Thanee M, Loilome W, Techasen A, et al (2015). Quantitative changes in tumor-associated M2 macrophages characterize cholangiocarcinoma and their association with metastasis. *Asian Pac J Cancer Prev*, **16**, 3043-50.
304. Thi Phung L, Loukas A, Brindley PJ, et al (2014). Retrotransposon OV-RTE-1 from the carcinogenic liver fluke *Opisthorchis viverrini*: potential target for DNA-based diagnosis. *Infection, Genetics & Evolution*, **21**, 443-51.
305. Thian YL, Riddell AM, Koh DM (2013). Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. *Cancer Imaging*, **13**, 567-79.
306. Thinkhamrop K, Khuntikeo N, Phonjitt P, et al (2015). Association between Diabetes Mellitus and Fatty Liver Based on Ultrasonography Screening in the World's Highest Cholangiocarcinoma Incidence Region, Northeast Thailand. *Asian Pac J Cancer Prev*, **16**, 3931-6.

307. Thohinung S, Kanokmedhakul S, Kanokmedhakul K, et al (2010). Cytotoxic 10-(indol-3-yl)-[13]cytochalasans from the fungus *Chaetomium elatum* ChE01. *Arch Pharm Res*, **33**, 1135-41.
308. Thongchot S, Loilome W, Yongvanit P, et al (2015). Chloroquine exerts anti-metastatic activities under hypoxic conditions in cholangiocarcinoma cells. *Asian Pac J Cancer Prev*, **16**, 2031-5.
309. Thongchot S, Yongvanit P, Loilome W, et al (2014). High expression of HIF-1alpha, BNIP3 and PI3KC3: hypoxia-induced autophagy predicts cholangiocarcinoma survival and metastasis. *Asian Pac J Cancer Prev*, **15**, 5873-8.
310. Thummarati P, Wijitburaphat S, Prasopthum A, et al (2012). High level of urokinase plasminogen activator contributes to cholangiocarcinoma invasion and metastasis. *World J Gastroenterol*, **18**, 244-50.
311. Thunyaharn N, Promthet S, Wiangnon S, et al (2013). Survival of cholangiocarcinoma patients in northeastern Thailand after supportive treatment. *Asian Pac J Cancer Prev*, **14**, 7029-32.
312. Tit-Oon P, Chokchaichamnankit D, Khongmanee A, et al (2014). Comparative secretome analysis of cholangiocarcinoma cell line in three-dimensional culture. *International Journal of Oncology*, **45**, 2108-16.
313. Tolek A, Wongkham C, Proungvitaya S, et al (2012). Serum alpha1beta-glycoprotein and afamin ratio as potential diagnostic and prognostic markers in cholangiocarcinoma. *Exp Biol Med (Maywood)*, **237**, 1142-9.
314. Tongtawee T, Kaewpitoon SJ, Loyd R, et al (2015). High Expression of Matrix Metalloproteinase-11 indicates Poor Prognosis in Human Cholangiocarcinoma. *Asian Pac J Cancer Prev*, **16**, 3697-701.

315. Treekitkarnmongkol W, Suthiphongchai T (2010). High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6K. *World J Gastroenterol*, **16**, 4047-54.
316. Treeprasertsuk S, Bjornsson E, Sinakos E, et al (2013). Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy. *World J Gastrointest Pharmacol Ther*, **4**, 61-8.
317. Tuskorn O, Prawan A, Senggunprai L, et al (2013a). Phenethyl isothiocyanate induces apoptosis of cholangiocarcinoma cells through interruption of glutathione and mitochondrial pathway. *Naunyn Schmiedebergs Arch Pharmacol*, **386**, 1009-16.
318. Tuskorn O, Senggunprai L, Prawan A, et al (2013b). Phenethyl isothiocyanate induces calcium mobilization and mitochondrial cell death pathway in cholangiocarcinoma KKU-M214 cells. *BMC Cancer*, **13**, 571.
319. Uthaisar K, Seubwai W, Srikoon P, et al (2012). Cepharanthine suppresses metastatic potential of human cholangiocarcinoma cell lines. *Asian Pac J Cancer Prev*, **13 Suppl**, 149-54.
320. Utispan K, Sonongbua J, Thuwajit P, et al (2012). Periostin activates integrin alpha5beta1 through a PI3K/AKTdependent pathway in invasion of cholangiocarcinoma. *Int J Oncol*, **41**, 1110-8.
321. Utispan K, Thuwajit P, Abiko Y, et al (2010). Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. *Mol Cancer*, **9**, 13.
322. Vaeteewoottacharn K, Seubwai W, Bhudhisawasdi V, et al (2014). Potential targeted therapy for liver fluke associated cholangiocarcinoma. *J Hepatobiliary Pancreat Sci*, **21**, 362-70.

323. Vanichapol T, Leelawat K, Hongeng S (2015). Hypoxia enhances cholangiocarcinoma invasion through activation of hepatocyte growth factor receptor and the extracellular signal-regulated kinase signaling pathway. *Mol Med Rep*, **12**, 3265-72.
324. Villar S, Ortiz-Cuaran S, Abedi-Ardekani B, et al (2012). Aflatoxin-induced TP53 R249S mutation in hepatocellular carcinoma in Thailand: association with tumors developing in the absence of liver cirrhosis. *PLoS One*, **7**, e37707.
325. Wasuworawong K, Roytrakul S, Paemanee A, et al (2015). Comparative Proteomic Analysis of Human Cholangiocarcinoma Cell Lines: S100A2 as a Potential Candidate Protein Inducer of Invasion. *Dis Markers*, **2015**, 629367.
326. Wattanawongdon W, Hahnvajanawong C, Namwat N, et al (2015). Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness. *Int J Oncol*, **47**, 398-410.
327. Watwiengkam N, Sithithaworn J, Duengngai K, et al (2013). Improved performance and quantitative detection of copro-antigens by a monoclonal antibody based ELISA to diagnose human opisthorchiasis. *Acta Trop*, **128**, 659-65.
328. Wee A (2011). Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis. *Cytopathology*, **22**, 287-305.
329. Weeraphan C, Diskul-Na-Ayudthaya P, Chiablaem K, et al (2012). Effective enrichment of cholangiocarcinoma secretomes using the hollow fiber bioreactor culture system. *Talanta*, **99**, 294-301.
330. Wijit A, Morakote N, Klinchid J (2013). High prevalence of haplorchiasis in Nan and Lampang provinces, Thailand, proven by adult worm recovery from suspected opisthorchiasis cases. *Korean J Parasitol*, **51**, 767-9.



331. Wirasorn K, Ngamprasertchai T, Khuntikeo N, et al (2013). Adjuvant chemotherapy in resectable cholangiocarcinoma patients. *J Gastroenterol Hepatol*, **28**, 1885-91.
332. Wirasorn K, Suwanrungruag K, Wiangnon S, et al (2014). Numbers of new cases and trends of cancer 1993-2012: srinagarind hospital based population, Khon Kaen, North-East Thailand. *Asian Pac J Cancer Prev*, **15**, 8423-7.
333. Wongba N, Thaewnongiew K, Phathee K, et al (2011). Liver fluke prevention and control in the northeast of Thailand through action research. *Asian Pac J Cancer Prev*, **12**, 1367-70.
334. Wongkham S, Silsirivanit A (2012). State of serum markers for detection of cholangiocarcinoma. *Asian Pac J Cancer Prev*, **13 Suppl**, 17-27.
335. Wonkchalee N, Boonmars T, Laummaunwai P, et al (2013). A combination of praziquantel and the traditional medicinal plant *Thunbergia laurifolia* on *Opisthorchis viverrini* infection and cholangiocarcinoma in a hamster model. *Parasitol Res*, **112**, 4211-9.
336. Wonkchalee O, Boonmars T, Aromdee C, et al (2012). Anti-inflammatory, antioxidant and hepatoprotective effects of *Thunbergia laurifolia* Linn. on experimental opisthorchiasis. *Parasitol Res*, **111**, 353-9.
337. Wonkchalee O, Boonmars T, Kaewkes S, et al (2011). *Opisthorchis viverrini* infection causes liver and biliary cirrhosis in gerbils. *Parasitol Res*, **109**, 545-51.
338. Woradet S, Promthet S, Songserm N, et al (2013). Factors affecting survival time of cholangiocarcinoma patients: a prospective study in Northeast Thailand. *Asian Pac J Cancer Prev*, **14**, 1623-7.
339. Woradet S, Promthet S, Songserm N, et al (2015). Factors Affecting Health-Related Quality of Life in Patients With Cholangiocarcinoma in the Northeastern Region of Thailand. *Cancer Nurs*, **38**, E46-51.

340. Worasith C, Kamamia C, Yakovleva A, et al (2015). Advances in the Diagnosis of Human Opisthorchiasis: Development of Opisthorchis viverrini Antigen Detection in Urine. *PLoS Negl Trop Dis*, **9**, e0004157.
341. Yonglitthipagon P, Pairojkul C, Chamgramol Y, et al (2012). Prognostic significance of peroxiredoxin 1 and ezrin-radixin-moesin-binding phosphoprotein 50 in cholangiocarcinoma. *Hum Pathol*, **43**, 1719-30.
342. Yonglitthipagon P, Pairojkul C, Chamgramol Y, et al (2010). Up-regulation of annexin A2 in cholangiocarcinoma caused by Opisthorchis viverrini and its implication as a prognostic marker. *International Journal for Parasitology*, **40**, 1203-12.
343. Yongvanit P, Phanomsri E, Namwat N, et al (2012a). Hepatic cytochrome P450 2A6 and 2E1 status in peri-tumor tissues of patients with Opisthorchis viverrini-associated cholangiocarcinoma. *Parasitol Int*, **61**, 162-6.
344. Yongvanit P, Pinlaor S, Bartsch H (2012b). Oxidative and nitrative DNA damage: key events in opisthorchiasis-induced carcinogenesis. *Parasitology International*, **61**, 130-5.
345. Yongvanit P, Pinlaor S, Loilome W (2014). Risk biomarkers for assessment and chemoprevention of liver fluke-associated cholangiocarcinoma. *J Hepatobiliary Pancreat Sci*, **21**, 309-15.
346. Yoo WG, Kim DW, Ju JW, et al (2011). Developmental transcriptomic features of the carcinogenic liver fluke, Clonorchis sinensis. *PLoS Negl Trop Dis*, **5**, e1208.
347. Yothaisong S, Dokduang H, Techasen A, et al (2013). Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. *Tumour Biol*, **34**, 3637-48.

348. Yothaisong S, Namwat N, Yongvanit P, et al (2015). Increase in L-type amino acid transporter 1 expression during cholangiocarcinogenesis caused by liver fluke infection and its prognostic significance. *Parasitol Int.*
349. Yothaisong S, Thanee M, Namwat N, et al (2014). Opisthorchis viverrini infection activates the PI3K/ AKT/PTEN and Wnt/beta-catenin signaling pathways in a Cholangiocarcinogenesis model. *Asian Pac J Cancer Prev*, **15**, 10463-8.
350. Young ND, Nagarajan N, Lin SJ, et al (2014). The Opisthorchis viverrini genome provides insights into life in the bile duct. *Nat Commun*, **5**, 4378.
351. Yusoff AR, Razak MM, Yoong BK, et al (2012a). Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia. *World J Gastroenterol*, **18**, 458-65.
352. Yusoff AR, Siti ZM, Muzammil AR, et al (2012b). Cholangiocarcinoma: a 10-year experience of a single tertiary centre in the multi ethnicity-Malaysia. *Med J Malaysia*, **67**, 45-51.
353. Zeekpudsa P, Kukongviriyapan V, Senggunprai L, et al (2014). Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents. *J Exp Clin Cancer Res*, **33**, 11.